BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 15882132)

  • 1. Pharmacogenetic studies of response to risperidone and other newer atypical antipsychotics.
    Lane HY; Lee CC; Liu YC; Chang WH
    Pharmacogenomics; 2005 Mar; 6(2):139-49. PubMed ID: 15882132
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of DRD2, 5-HT2A, and COMT genes on antipsychotic response to risperidone.
    Yamanouchi Y; Iwata N; Suzuki T; Kitajima T; Ikeda M; Ozaki N
    Pharmacogenomics J; 2003; 3(6):356-61. PubMed ID: 14610521
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of dopamine D2 receptor Ser311Cys polymorphism and clinical factors on risperidone efficacy for positive and negative symptoms and social function.
    Lane HY; Lee CC; Chang YC; Lu CT; Huang CH; Chang WH
    Int J Neuropsychopharmacol; 2004 Dec; 7(4):461-70. PubMed ID: 15140279
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Variants of dopamine and serotonin candidate genes as predictors of response to risperidone treatment in first-episode schizophrenia.
    Ikeda M; Yamanouchi Y; Kinoshita Y; Kitajima T; Yoshimura R; Hashimoto S; O'Donovan MC; Nakamura J; Ozaki N; Iwata N
    Pharmacogenomics; 2008 Oct; 9(10):1437-43. PubMed ID: 18855532
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association between T102C and A-1438G polymorphisms in the serotonin receptor 2A (5-HT2A) gene and schizophrenia: relevance for treatment with antipsychotic drugs.
    Peñas-Lledó EM; Dorado P; Cáceres MC; de la Rubia A; Llerena A
    Clin Chem Lab Med; 2007; 45(7):835-8. PubMed ID: 17617023
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dopamine (DRD2) and Serotonin (HTR2A, 2C) Receptor Gene Polymorphisms do not influence early response to Risperidone in South Indian Patients with Schizophrenia.
    Alladi CG; RajKumar RP; Adithan S; Marie-Claire C; Bellivier F; Shewade DG
    Fundam Clin Pharmacol; 2019 Jun; 33(3):355-364. PubMed ID: 30332506
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Risperidone-related weight gain: genetic and nongenetic predictors.
    Lane HY; Liu YC; Huang CL; Chang YC; Wu PL; Lu CT; Chang WH
    J Clin Psychopharmacol; 2006 Apr; 26(2):128-34. PubMed ID: 16633140
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association of risperidone treatment response with a polymorphism in the 5-HT(2A) receptor gene.
    Lane HY; Chang YC; Chiu CC; Chen ML; Hsieh MH; Chang WH
    Am J Psychiatry; 2002 Sep; 159(9):1593-5. PubMed ID: 12202283
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Could HTR2A T102C and DRD3 Ser9Gly predict clinical improvement in patients with acutely exacerbated schizophrenia? Results from treatment responses to risperidone in a naturalistic setting.
    Kim B; Choi EY; Kim CY; Song K; Joo YH
    Hum Psychopharmacol; 2008 Jan; 23(1):61-7. PubMed ID: 17924589
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of genetic correlates of response to Risperidone: Findings of a multicentric schizophrenia study from India.
    Kaur G; Gupta D; Chavan BS; Sinhmar V; Prasad R; Tripathi A; Garg PD; Gupta R; Khurana H; Gautam S; Margoob MA; Aneja J
    Asian J Psychiatr; 2017 Oct; 29():174-182. PubMed ID: 28692863
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparing the influence of dopamine D₂ polymorphisms and plasma drug concentrations on the clinical response to risperidone.
    Yasui-Furukori N; Tsuchimine S; Saito M; Nakagami T; Sugawara N; Fujii A; Kaneko S
    J Clin Psychopharmacol; 2011 Oct; 31(5):633-7. PubMed ID: 21869689
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Negative symptoms of schizophrenia could explain discrepant data on the association between the 5-HT2A receptor gene and response to antipsychotics.
    Hamdani N; Bonnière M; Adès J; Hamon M; Boni C; Gorwood P
    Neurosci Lett; 2005 Mar; 377(1):69-74. PubMed ID: 15722190
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gene polymorphism influencing treatment response in psychotic patients in a naturalistic setting.
    Alenius M; Wadelius M; Dahl ML; Hartvig P; Lindström L; Hammarlund-Udenaes M
    J Psychiatr Res; 2008 Sep; 42(11):884-93. PubMed ID: 18086475
    [TBL] [Abstract][Full Text] [Related]  

  • 14. DRD2 promoter region variation as a predictor of sustained response to antipsychotic medication in first-episode schizophrenia patients.
    Lencz T; Robinson DG; Xu K; Ekholm J; Sevy S; Gunduz-Bruce H; Woerner MG; Kane JM; Goldman D; Malhotra AK
    Am J Psychiatry; 2006 Mar; 163(3):529-31. PubMed ID: 16513877
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Functional serotonin 1A receptor variant influences treatment response to atypical antipsychotics in schizophrenia.
    Mössner R; Schuhmacher A; Kühn KU; Cvetanovska G; Rujescu D; Zill P; Quednow BB; Rietschel M; Wölwer W; Gaebel W; Wagner M; Maier W
    Pharmacogenet Genomics; 2009 Jan; 19(1):91-4. PubMed ID: 18849890
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association study between HTR2A rs6313 polymorphism and early response to risperidone and olanzapine in schizophrenia patients.
    Maffioletti E; Valsecchi P; Minelli A; Magri C; Bonvicini C; Barlati S; Sacchetti E; Vita A; Gennarelli M
    Drug Dev Res; 2020 Sep; 81(6):754-761. PubMed ID: 32462699
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The --1019 C/G polymorphism of the 5-HT(1)A receptor gene is associated with negative symptom response to risperidone treatment in schizophrenia patients.
    Wang L; Fang C; Zhang A; Du J; Yu L; Ma J; Feng G; Xing Q; He L
    J Psychopharmacol; 2008 Nov; 22(8):904-9. PubMed ID: 18308786
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association between dopamine receptor gene polymorphisms and effects of risperidone treatment: A systematic review and meta-analysis.
    Ma L; Zhang X; Xiang Q; Zhou S; Zhao N; Xie Q; Zhao X; Zhou Y; Cui Y
    Basic Clin Pharmacol Toxicol; 2019 Jan; 124(1):94-104. PubMed ID: 30103286
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacogenetics of dopamine receptors and response to antipsychotic drugs in schizophrenia--an update.
    Scharfetter J
    Pharmacogenomics; 2004 Sep; 5(6):691-8. PubMed ID: 15335289
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Optimization of maintenance therapy of Risperidone with CYP2D6 genetic polymorphisms through an extended translational framework-based prediction of target occupancies/clinical outcomes.
    Li HQ; Xu JY; Gao YY; Jin L
    Pharmacol Res; 2018 Nov; 137():135-147. PubMed ID: 30281999
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.